Search

Displaying results 1561 - 1570 of 1901 in total
  1. Drug

    Tisagenlecleucel

    go.drugbank.com/drugs/DB13881
    ApprovedInvestigational

    It was granted approval by FDA in August 2017 under the market name Kymriah. … Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric antigen receptor

    Categories: CD19 Receptor Interactions, CD19-directed Chimeric Antigen Receptor
  2. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    FDA approved nerandomilast tablets for the treatment of progressive pulmonary fibrosis (PPF) in adults.

  3. Drug

    BMS-564929

    go.drugbank.com/drugs/DB07286
    Experimental

    So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause. … BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM).

  4. Drug

    Cannabidivarin

    go.drugbank.com/drugs/DB14050
    Investigational

    The anti-epileptic activity of CBD and CBDV is thought to be modulated by their effects on transient receptor potential cation channel subfamily V member 1 (TRPV1), also known as the capsaicin receptor

  5. Drug

    Denufosol

    go.drugbank.com/drugs/DB04983
    Investigational

    Denufosol has not gained FDA approval, and clinical trials with this drug have ceased since 2011. … A new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol.

  6. Drug

    Olopatadine

    go.drugbank.com/drugs/DB00768
    Approved

    An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively.

  7. Drug

    Glycopyrronium

    go.drugbank.com/drugs/DB00986
    ApprovedInvestigationalVet approved

    [A233565] Glycopyrronium was originally granted FDA approval on 11 August 1961.[L33090]

  8. Drug

    Rotigotine

    go.drugbank.com/drugs/DB05271
    ApprovedInvestigational

    It was approved by the European Medicines Agency in 2006 and by the FDA in 2007.

    Categories: Serotonin Receptor Agonists, Serotonin 5-HT1 Receptor Agonists
  9. Drug

    Plasma protein fraction (human)

    go.drugbank.com/drugs/DB13968
    ApprovedInvestigational

    [A32512] It is already reviewed under the category of biologics by the FDA where the processing, required tests, requirements and labeling are incorporated.

  10. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    [L63934] The FDA approved centanafadine on July 24, 2026, for the treatment of ADHD in adults and pediatric patients 6 years of age and older weighing at least 20 kg; use is not recommended below that